Published in Drug Law Weekly, May 3rd, 2005
The patent protects key intellectual property exclusively licensed to ARC that may be used in the development of ARC's lead product candidates for the treatment of surgical adhesions.
"This issued patent strengthens ARC's intellectual property portfolio," said Chuck Winternitz, director of operations for ARC. "The polymers included broaden the company's pipeline and may be useful in the development of films, gels and instillates for the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.